Chongqing Genrix Biopharmaceutical's (SHA:688443) Teliqibaimab injection achieved its primary endpoint in a phase 3 clinical trial, according to a Friday filing with the Shanghai bourse.
The drug is indicated for the treatment of moderate to severe atopic dermatitis in adults, according to the drug company's filing.
Shares closed 1% higher during afternoon trading on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments